Person:
Davids, Matthew

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Davids

First Name

Matthew

Name

Davids, Matthew
Author's Publications: search.filters.isAuthorOfPublication.31fee75b-158a-4f6e-95f3-c95f86fe4ac2

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
    (American Association for Cancer Research (AACR), 2016) Montero, Juan; Stephansky, Jason; Cai, Tianyu; Griffin, Gabriel; Cabal-Hierro, Lucia; Togami, Katsuhiro; Hogdal, Leah J.; Galinsky, Ilene; Morgan, Elizabeth; Aster, Jon; Davids, Matthew; Leboeuf, Nicole; Stone, Richard; Konopleva, Marina; Pemmaraju, Naveen; Letai, Anthony; Lane, Andrew
    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the anti-apoptotic protein BCL-2 and were uniformly sensitive to the BCL-2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on two patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL-2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker.
  • Thumbnail Image
    Publication
    Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
    (BioMed Central, 2018) Gosangi, Babina; Davids, Matthew; Somarouthu, Bhanusupriya; Alessandrino, Francesco; Giardino, Angela; Ramaiya, Nikhil; Krajewski, Katherine
    The last 5 years have been marked by profound innovation in the targeted treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas. Using CLL as a case study, we present a timeline and overview of the current treatment landscape for the radiologist, including an overview of clinical and radiological features of CLL, discussion of the targeted agents themselves, and the role of imaging in response and toxicity assessment. The goal is to familiarize the radiologist with multiple Food and Drug Administration (FDA)-approved targeted agents used in this setting and associated adverse events which are commonly observed in this patient population.